Sobre el grupo
Investigador Principal
David Fernández Antorán
Equipo
Ines Ortiz de Solórzano, Marina Sanz Gracia
Hospital Universitario Miguel Servet
Líneas de Investigación
ESTUDIO DE LAS REPUESTAS DE TUMORES ESCAMOSOS A TRATAMIENTOS USANDO EPITELIOIDES HUMANOS
DESARROLLO DE NUEVOS TRATAMIENTOS EN RADIOTERAPIA Y QUIMIOTERAPIA
ESTUDIO DE NUEVAS TERAPIAS BASADAS EN EL USO DE NANOANTICUERPOS Y NANOPARTICULAS
ESTUDIO DE ONCOTRIPSIS USANDO MODELOS AVANZADOS EN 3D (EPITELIOIDES)
Publicaciones más relevantes
Albert Herms*, David Fernandez-Antoran*, Maria P. Alcolea*, Argyro Kalogeropoulou, Ujjwal Banerjee, Gabriel Piedrafita, Emilie Abby, Jose Antonio Valverde-Lopez, Inês S.
Ferreira, Stefan C. Dentro, Swee Hoe Ong, Bartomeu Colom, Kasumi Murai, Charlotte King, Krishnaa Mahbubani, Kourosh Saeb-Parsy, Alan R Lowe, Moritz Gerstung, Philip H
Jones. Self-sustaining long-term 3D epithelioid cultures reveal drivers of clonal expansion in esophageal epithelium. Nature Genetics, 2024.
https://doi.org/10.1038/s41588-024-01875-8 *co-first authors. (1er decil).
Albert Herms*, Bartomeu Colom*, Gabriel Piedrafita, Emilie Abby, Kasumi Murai, Charlotte King, Swee Hoe Ong, David Fernandez-Antoran, Michael W J Hall, Christopher Bryant, Roshan K Sood, Joanna C Fowler, Christian Frezza, Bart Vanhaesebroeck, Philip H Jones.Organismal metabolism regulates the expansion of oncogenic PIK3CA mutant clones in normal esophagus. Nature Genetics, 2024.
https://doi.org/10.1038/s41588-024-01891-8 * co-first authors. (1er decil)
Regina Hoo*, Elias R. Ruiz-Morales*, Iva Kelava, Mukul Rawat, Cecilia Icoresi Mazzeo, Elizabeth Tuck, Carmen Sancho-Serra, Sara Chelaghma, Alexander V. Predeus, Simon Murray, David Fernandez-Antoran, Ross F. Waller, Damiana Álvarez-Errico, Marcus C.S. Lee, Roser Vento-Tormo. Early infection response of the first trimester human placenta at single-cell scale. Cell Systems, 2024
https://doi.org/10.1016/j.cels.2024.04.002 * co-first authors. (1er decil)
Kasumi Murai, Stefan Dentro, Swee Hoe Ong, Roshan Sood, David FernandezAntoran, Albert Herms, Vasiliki Kostiou, Benjamin A Hall, Moritz Gerstung, Philip H Jones. p53 mutation in normal esophagus promotes multiple stages of carcinogenesis but is constrained by clonal competition. Nat Commun 13, 6206 (2022).
https://doi.org/10.1038/s41467-022-33945-y. (1er decil)
B. Colom, A. Herms, M. W. J. Hall, S. C. Dentro, C. King, R. K. Sood, M. P. Alcolea, G. Piedrafita, D. Fernandez-Antoran, S. H. Ong, J. C. Fowler, K. T. Mahbubani, K. SaebParsy, M. Gerstung, B. A. Hall & P. H. Jones. Mutant clones in normal epithelium outcompete and eliminate emerging tumours. Nature
https://doi.org/10.1038/s41586-021-03965-7. (1er decil)
Joanna Fowler, Charlotte King, Christopher Bryant, Michael Hall, Roshan Sood, Swee Hoe Ong, Eleanor Earp, David Fernandez-Antoran, Jonas Koeppel, Stefan Dentro, David Shorthouse, Amer Durrani, Kate Fife, Edward Rytina, Doreen Milne, Amit Roshan, Krishnaa Mahububani, Kourosh Saeb-Parsy, Benjamin Hall, and Moritz Gerstung, Philip H Jones. Selection of oncogenic mutant clones in normal human skin varies with body site. Cancer Discovery, October 21 (2020).
https://doi.org/10.1158/2159-8290.CD-20-1092. (1er decil)
Gabriel Piedrafita, Vasiliki Kostiou, Agnieszka Wabik, Bartomeu Colom, David Fernandez Antoran, Albert Herms, Kasumi Murai, Benjamin A Hall, Philip H Jones. A singleprogenitor model as the unifying paradigm of epidermal and esophageal epithelial maintenance in mice. Nat Commun 11, 1429 (2020).
https://doi.org/10.1038/s41467-020-15258-0. (1er decil)
David Fernandez-Antoran, Gabriel Piedrafita, Kasumi Murai, Swee How, Albert Herms, Christian Frezza and Philip H. Jones. Outcompeting p53-mutant cells in the normal esophagus by redox manipulation. Cell Stem Cell, 2019.
https://doi.org/10.1016/j.stem.2019.06.011 (1er decil)
Cristina Uruén, Jorge Gimeno , Marina Sanz, Lorenzo Fraile, Clara M. Marín, Jesús Arenas. Invasive Streptococcus suis isolated in Spain contain a highly promiscuous and dynamic resistome. Frontiers in Cellular and Infection Microbiology Vol.13, 2024.
https://doi.org/10.3389/fcimb.2023.1329632 (1 er cuartil)
Pilar Espiau-Romera, Andrés Gordo-Ortiz, Inés Ortiz-de-Solórzano, Patricia Sancho. Metabolic features of tumor-derived extracellular vesicles: challenges and opportunities. Extracellular Vesicles and Circulating Nucleic Acids, 2024.
https://doi.org/10.20517/evcna.2024.12 (3er cuartil)
Otra Actividad
2020- CRUK-RadNet funding grant (C17918/A28870, PRAG/015, 1.334.000€). The Gurdon Institute, University of Cambridge. Group Leader / Principal Investigator.. Uso de
epitelioides humanos y de raton para estudiar los efectos de la radioterapia y la evolucion clonal en tumores y tejido normal https://www.gurdon.cam.ac.uk/people/david-fernandezantoran/ David Fernandez Antoran En calidad de IP.
2021- Isaac Newton Trust / Wellcome Trust ISSF / University of Cambridge Joint Research Grant Scheme (PRAG/025) “In vitro responses of normal epithelial tissues to ionising radiation” (75.400€). David Fernandez Antoran. En calidad de IP.
2021 - Sunway University (Malaysia) - University of Cambridge joint grant. “Effect of lowdose ionising radiation on Nasopharyngeal carcinoma responses”. (116.000€). Financiacion de una estudiante de doctorado (Ms. Raahilah Zahir Essa) y el proyecto. David Fernandez Antoran. En calidad de IP y co-supervisor de Tesis.
2022 - Wellcome/Cancer Research UK Gurdon Institute. (290.000€). Institute Wellcome Trust funding awarded. David Fernandez Antoran. En calidad de IP
2022- CRUK-RadNet infrastructure funding on FLASH radiotherapy. University of Manchester and University of Cambridge. (232.000€). Prof. Karen Kirkby and Prof. Sir Steve Jackson. Irradiacion FLASH en la Universidad de Manchester (Proton Beam Therapy Centre) y en la Universidad de Oxford (Dr. Kristoffer Petersson). David Fernandez Antoran. En calidad de colaborador.
2022- NCR3’s-CRUK grant (86.194€) “Long-term, self-maintaining primary 3D cultures of mouse and human epithelial tissues for reduction and replacement of animals in research”.
https://www.nc3rs.org.uk/our-portfolio/long-term-self-maintaining-primary-3d-culturesmouse-and-human-epithelial-tissues. David Fernandez Antoran. En calidad de IP
2022- Emerging Radiotherapy Technologies CRUK-RadNet seed grant (73.080€). “Investigating Proton and Electron FLASH radiotherapies in Novel 3D Epithelioid cultures. Financiacion de una postdoc (Dr. Eirini Terpsi Vitti) para estudiar el efecto FLASH in vitro utilizando Epitelioides tumorales de ratón y cultivos 2D. Principal Investigator. David Fernandez Antoran. En calidad de IP
2023-CRUK RadNet Cambridge Development Fund (52.019€): “Hamlet.RT.Collect”. Estudio de la evolucion del cancer de cabeza y cuello durante los tratamienots de radioterapia usando Epitelioides humanos de cancer escamoso. Dr. Gill Barnett (Cambridge University Hospital - Department of Oncology). David Fernandez Antoran. En calidad de colaborador.
2023- CRUK-RadNet pump priming (23.200€): “Investigation into Immune Cell Response Across a Micro Proton Spread Out Bragg Peak in a Novel 3D Epithelioid Tissue Sample”. (Dr. John Warmenhoven). David Fernandez Antoran. En calidad de co-solicitante e IP.
2024- Estudio de oncotripsis usando modelos avanzados en 3D (Epithelioids). David Fernandez Antoran en colaboración con Prof. Manuel Doblaré, Prof. Ignacio Ochoa, Prof. Miguel Ortiz, Dr. Alberto Jimenez Schuhmacher, Guillermo Rus Calborg. Avance de crédito IIS-Aragon (20.000€)
2024- Estudio de nuevas terapias basadas en nanoanticuerpos y nanopartículas. Dr. David Fernandez Antoran, Ines Ortiz de Solórzano, Marina Sanz Gracia, Dr. Alberto Jimenez Schuhmacher, Dr. Alberto Pradilla Dieste, Dr. Marta Baselga, Dr. Carlos Caro Salazar. Fondos propios anteriormente obtenidos.